Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NOTA-3P-TATE-RGD PET/CT in Lung Cancer and Neuroendocrine Neoplasms
NCT02817945Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2016
- Primary completion
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68-NOTA-3PTATE-RGD in lung cancer and Neuroendocrine neoplasm (NEN), sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value at 1 year. Status: unknown.
02
Drugs
gallium Ga 68-NOTA-3PTATE-RGD
03
Conditions
lung cancerNeuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT02817945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02817945.